关于糖尿病视网膜病变的当前药理疗法的最新情况
Sofía M Muns1, Victor M Villegas1,2, Harry W Flynn2
1Department of Ophthalmology, University of Puerto Rico, San Juan, Puerto Rico.
Expert opinion on pharmacotherapy
|July 11, 2023
概括
糖尿病视网膜病变治疗正在发展,抗VEGF治疗和皮质类固醇是关键的选择. 新兴疗法旨在改善糖尿病黄斑和糖尿病增殖性视网膜病变的结果.
科学领域:
- 眼科医生 眼科 眼科
- 内分泌学 在内分泌学.
- 药理学 药理学是指药理学的学科.
背景情况:
- 糖尿病视网膜病变是全球视力障碍的主要原因之一.
- 关键的临床表现包括糖尿病黄斑 (DME) 和增殖性糖尿病视网膜病变 (PDR).
研究的目的:
- 审查目前和新兴的糖尿病视网膜病变的药理疗法.
- 突出在管理DME和PDR方面的进步.
主要方法:
- 使用PubMed进行的文献综述.
- 包括1995年至2023年间发表的文章.
主要成果:
- 静脉内抗血管内皮生长因子 (VEGF) 治疗是DME和PDR的主要治疗方法.
- 皮质类固醇作为基本的二线治疗DME.
- 研究正在探索新的炎症调解剂和新疗法的信号通路.
结论:
- 新兴的治疗方法,包括新的抗VEGF药物,整蛋白抗剂和抗炎药物,显示出有前途.
- 这些新的方法可能会提高治疗效率,并减少患者在治疗糖尿病视网膜病变方面的负担.
相关概念视频
Diabetes: Management and Pharmacotherapy
319
The therapy for diabetes aims to alleviate hyperglycemia-related symptoms, prevent acute metabolic decompensation, and reduce chronic end-organ complications. Glycemic control is evaluated through short-term (self-monitoring, continuous glucose monitoring) and long-term (A1c, fructosamine) metrics, enabling near real-time tracking of blood glucose levels and reflecting glycemic control over specific time frames.
Insulin remains the cornerstone of treatment for most patients with type 1 and many...
Insulin remains the cornerstone of treatment for most patients with type 1 and many...
319
Open Angle Glaucoma: Treatment
481
In open-angle glaucoma, the iridocorneal angle remains open, but the trabecular meshwork becomes stiff, slowing down the outflow of aqueous humor. This causes a buildup of aqueous humor in the anterior chamber, leading to a sudden increase in intraocular pressure. The treatment for open-angle glaucoma focuses on reducing the elevated intraocular pressure by either decreasing the secretion of aqueous humor or increasing its outflow.
Drugs such as carbonic anhydrase inhibitors, α2- and...
Drugs such as carbonic anhydrase inhibitors, α2- and...
481
Hypertension IV: Drug Therapy and Lifestyle Modifications
17
Multiple classes of antihypertensive medications are employed in treating hypertension. The most commonly recommended first-line treatments include:Thiazide Diuretics, such as chlorthalidone, increase sodium and water excretion from the body, reducing blood volume and blood pressure.Angiotensin-converting enzyme inhibitors, like lisinopril, block the conversion of angiotensin I to II, a potent vasoconstrictor lowering blood pressure.Angiotensin II Receptor Blockers (ARBs) prevent angiotensin II...
17
Heart Failure V: Medical Management
14
Medical Management of Acute Decompensated Heart Failure (ADHF)The primary goals of therapy for patients hospitalized with acute decompensated heart failure (ADHF) include:Relieving symptomsOptimizing volume statusSupporting oxygenation and ventilationMaintaining cardiac output (CO) and end-organ perfusionIdentifying and addressing the cause of ADHFPreventing complicationsProviding patient education on factors precipitating HF exacerbationPlanning for dischargeOngoing monitoring and assessment...
14
Oral Hypoglycemic Agents: Biguanides and Glitazones
236
Biguanides, particularly metformin (Glucophage), are insulin sensitizers that enhance glucose uptake, thereby reducing insulin resistance. Unlike sulfonylureas, metformin doesn't prompt insulin secretion, which helps to curb hypoglycemia risk. Metformin is beneficial in treating conditions like polycystic ovary syndrome due to its insulin-resistance reduction capability. The drug's primary action involves curtailing hepatic gluconeogenesis, a significant contributor to high blood...
236
Angle Closure Glaucoma: Treatment
574
Angle-closure glaucoma, or closed-angle glaucoma, is an eye condition where the iris bulges out and blocks the iridocorneal angle, resulting in a buildup of aqueous humor and increased intraocular pressure. Immediate medical attention is necessary due to the sudden onset of symptoms. The treatment for angle-closure glaucoma includes short-term and long-term approaches. Short-term treatment involves using eye drops like pilocarpine to lower intraocular pressure by increasing aqueous humor...
574


